Torrent Pharmaceuticals Quarterly Results for Trading Insights
In Mar 2026, Torrent Pharmaceuticals (TORNTPHARM) reported revenue ₹4,111 Cr and net profit ₹364 Cr — revenue +42.2% YoY. View TORNTPHARM 52-week performance for the annual high/low range and current price position.
TORNTPHARM Quarterly Results — Revenue, Profit & EPS Highlights
Torrent Pharmaceuticals latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. Analyse TORNTPHARM institutional holdings to track promoter, FII and institutional holdings.
- Revenue of ₹4,111 Cr in Mar 2026 (+27.7% vs Sept 2025, +42.2% vs Mar 2025)
- Net Profit of ₹364 Cr in Mar 2026 (-38.4% vs Sept 2025, -26.9% vs Mar 2025)
- EBITDA of ₹1,204 Cr in Mar 2026 (+22.0% vs Sept 2025)
- Operating Margin of 30.0% in Mar 2026 (-1.0pp vs Sept 2025)
- Earnings Per Share of ₹11.51 in Mar 2026 (-34.4% vs Sept 2025)
Torrent Pharmaceuticals Quarterly Results — Revenue, EBITDA, Net Profit & EPS
TORNTPHARM quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Mar 2026 | Sept 2025 | Mar 2025 | Jun 2025 | Dec 2025 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 4,111 | 3,219 | 2,891 | 3,091 | 3,238 | 27.7% | 42.2% |
| Net Profit (₹ Cr) | 364 | 591 | 498 | 548 | 635 | - | - |
| EBITDA (₹ Cr) | 1,204 | 987 | 872 | 945 | 1,013 | - | - |
| EPS (₹) | 11.51 | 17.54 | 14.71 | 16.19 | 18.77 | - | - |
| Operating Margin (%) | 30.0% | 31.0% | 31.0% | 31.0% | 32.0% | - | - |
TORNTPHARM Share Price Trend — 1-Year Movement Across Quarterly Results
Torrent Pharmaceuticals 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. For annual financials, live price and key ratios, visit TORNTPHARM share price screener.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
TORNTPHARM vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Torrent Pharmaceuticals latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Mar 2026 |
₹441,477.63 Cr | 1837.3 | 15,018 | 2,710 | -5.6% | - | 18.0% | 162.6 |
|
Divis Laboratories
Mar 2026 |
₹247,469.81 Cr | 9375.0 | 2,986 | 751 | -5.0% | - | 25.2% | 331.2 |
|
Zydus Life Science
Mar 2026 |
₹112,607.65 Cr | 1160.0 | 7,569 | 1,341 | -4.3% | - | 17.7% | 91.7 |
|
Cipla
Mar 2026 |
₹109,705.39 Cr | 1394.5 | 6,612 | 543 | -9.3% | - | 8.2% | 203.0 |
|
Laurus Labs
Mar 2026 |
₹103,852.21 Cr | 1954.0 | 1,823 | 282 | -10.5% | - | 15.5% | 377.9 |
All amounts in ₹ Crores